

Javier Campos-Gómez and Eriel Martínez Corresponding author(s): Last updated by authors on12/20/2018

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

~· ·· ··	
statistical	l parameters

When statistical analyses are reported	, confirm that the following items are	present in the relevant	location (e.g. figu	re legend, table	legend, mair
text, or Methods section).					

n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistics including <u>central tendency</u> (e.g. means) or other basic estimates (e.g. regression coefficient) AND <u>variation</u> (e.g. standard deviation) or associated <u>estimates of uncertainty</u> (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Clearly defined error bars State explicitly what error bars represent (e.g. SD, SE, CI)

Our web collection on statistics for biologists may be useful.

Software and code

Policy information about availability of computer code

Data collection No software was used Data analysis Prism 7 for Windows, version 7.02

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data supporting the findings of this study are available within the article and its supplementary information files, or from the corresponding author on request.

Field-spe	cific reporting			
Please select the be	est fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences			
For a reference copy of t	he document with all sections, see <u>nature.com/authors/policies/ReportingSummary-flat.pdf</u>			
Life scier	ices study design			
All studies must dis	close on these points even when the disclosure is negative.			
Sample size	Experiments were done at least by triplicate following what is generally accepted for the kind of experiments performed in this study by the scientific community.			
Data exclusions	ata exclusions No data were excluded.			
Replication	All attempts at replication were succesful.			
Randomization	This is not relevant to our study.			
Blinding	This is not relevant to our study.			
Reportin	g for specific materials, systems and methods			
	<u> </u>			
n/a Involved in th	erimental systems e study Methods n/a Involved in the study			
	logical materials ChIP-seq			
Antibodies	Flow cytometry			
Eukaryotic	cell lines MRI-based neuroimaging			
Palaeontol				
	Animals and other organisms Human research participants			
Unique biological materials				
Policy information about <u>availability of materials</u>				
Obtaining unique	materials All unique materials are readily available from the authors or commercially standard sources.			
Antibodies				
Antibodies used	Anti-6X His tag® antibody (HRP) conjugate (abcam) (ab1269)			
Validation	This antibody was validated using His-tagged and not tagged proteins.			
Eukaryotic cell lines				
Policy information about <u>cell lines</u>				
Cell line source(s	Cell line source(s) None cell line was used.			
Authentication	Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.			

Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for

mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

Mycoplasma contamination

Commonly misidentified lines (See ICLAC register)

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

Palaeontology

Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new

 $\centsymbol{ extstyle}$ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals

N/A

Wild animals

Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals

Field-collected samples

For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

Human research participants

Policy information about studies involving human research participants

Population characteristics

N/A

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

ChIP-seq

Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission

Provide a list of all files available in the database submission.

Genome browser session (e.g. UCSC)

Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

Methodology

Replicates

Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth

Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.

Antibodies

Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.

Peak calling parameters

Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.

Data quality

Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

Flow Cytometr

Plots		
Confirm that:		
The axis labels state the m	arker and fluorochrome used (e.g. CD4-FITC).	
The axis scales are clearly	visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).	
All plots are contour plots	with outliers or pseudocolor plots.	
A numerical value for num	ber of cells or percentage (with statistics) is provided.	
Methodology		
Sample preparation	Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.	
Instrument	Identify the instrument used for data collection, specifying make and model number.	
Software	Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.	
Cell population abundance	Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.	
Gating strategy	Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.	
Magnetic resonance Experimental design	imaging	
	Indicate task or resting state; event-related or block design.	
Design type		
Design specifications	Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.	
Behavioral performance meas	State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).	
Acquisition		
Imaging type(s)	Specify: functional, structural, diffusion, perfusion.	
Field strength	Specify in Tesla	
Sequence & imaging paramete	Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.	
Area of acquisition	State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.	
Diffusion MRI Used	Not used	
Preprocessing		

Normalization

Normalization template

Noise and artifact removal

Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, Preprocessing software segmentation, smoothing kernel size, etc.).

If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types

used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.

Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g.original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.

Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).

Volume censoring	Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.			
Statistical modeling & inference				
Model type and settings	Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).			
Effect(s) tested	Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.			
Specify type of analysis: Whole brain ROI-based Both				
Statistic type for inference (See <u>Eklund et al. 2016</u>)	Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.			
Correction	Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).			
Models & analysis				
n/a Involved in the study Functional and/or effective connectivity Graph analysis Multivariate modeling or predictive analysis				
Functional and/or effective connective	Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).			
Graph analysis	Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).			
Multivariate modeling and predictive	analysis Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.			